Clonal Evolution in Follicular Lymphoma
NCT03190928 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2026-05-22
Summary
Background:
Follicular lymphoma is a type of cancer of the lymph nodes. Lab studies are important for cancer research. They help scientists better understand differences in the cancer biology of different patients. Researchers want to collect serial samples over time from people with follicular lymphoma to help them design future treatments.
Objective:
To collect a variety of samples from people with follicular lymphoma to study how these diseases progress and respond to treatment.
Eligibility:
Adults at least 18 years old who have been diagnosed with, but have not yet had any treatment for, follicular lymphoma.
Design:
Participants will be screened with medical history and physical exam. They will answer questions about daily functioning. They will have blood and urine tests. They may have scans and have tissue samples taken.
Participants will be monitored about every 4 months for up to 2 years. They will repeat screening tests. They will have a cheek swab. A small brush will be rubbed against the inside of the cheek to wipe off some cells.
Participants will have imaging scans about every 8 months for up to 2 years.
Participants may have a bone marrow aspiration and biopsy. The hipbone will be numbed with a small needle.
A needle will be put into the hipbone, and about 2 tablespoons of bone marrow will be taken out through the needle.
Participants will continue being monitored every 6 months for up to 5 years, then 1 time a year.
...
Conditions
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Rahul Lakhotia, M.D. · National Cancer Institute (NCI)
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-07-27
- Primary Completion
- 2029-01-01
- Completion
- 2029-01-01
Countries
- United States
Study Locations
More Related Trials
-
Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma
NCT01130194 ·Status: COMPLETED ·Phase: PHASE2
-
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
NCT05058404 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
T-Cell Project: Epidemiologic Component
NCT00705809 ·Status: COMPLETED
-
Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab
NCT01150643 ·Status: COMPLETED
-
Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial
NCT05816850 ·Status: RECRUITING
-
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
NCT00001512 ·Status: COMPLETED ·Phase: PHASE1
-
High-Dose Therapy Treatment in Patients With Follicular Lymphoma
NCT00696735 ·Status: COMPLETED ·Phase: PHASE3
-
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
NCT02031419 ·Status: TERMINATED ·Phase: PHASE1
-
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
NCT02871219 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients
NCT00949741 ·Status: COMPLETED
-
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
NCT02592876 ·Status: TERMINATED ·Phase: PHASE2
-
Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden
NCT00136552 ·Status: COMPLETED ·Phase: PHASE3
-
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
NCT05422521 ·Status: RECRUITING ·Phase: NA
-
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
NCT02855359 ·Status: TERMINATED ·Phase: PHASE2
-
Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma
NCT01393756 ·Status: COMPLETED ·Phase: PHASE2
-
Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma
NCT00774826 ·Status: UNKNOWN ·Phase: PHASE3
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma
NCT00003204 ·Status: COMPLETED ·Phase: PHASE3
-
Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT05052528 ·Status: RECRUITING ·Phase: PHASE1
-
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
NCT00670358 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinical Outcomes of Early-progressed Follicular Lymphoma in Korea
NCT04048395 ·Status: UNKNOWN
-
Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma
NCT00227695 ·Status: COMPLETED ·Phase: PHASE3
-
Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma
NCT05338879 ·Status: COMPLETED
-
Randomized Study for Patients With Follicular Lymphoma Needing Treatment
NCT00140569 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)
NCT02038933 ·Status: COMPLETED ·Phase: PHASE2